Quantcast

Latest Isis Stories

2014-06-03 08:31:23

CARLSBAD, Calif., June 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2014 Annual Meeting of Stockholders and Open House on Tuesday, June 10 at 2:10 p.m. Pacific Time in Carlsbad, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO The agenda for the meeting is as follows:2:00 p.m. - 2:10 p.m. Annual Meeting of...

2014-05-22 08:28:45

Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXI(Rx) undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor...

2014-05-20 08:31:54

CARLSBAD, Calif., May 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKK(Rx). ISIS-PKK(Rx) is an antisense drug in development to treat patients with hereditary angioedemia (HAE). HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE affects approximately 20,000 patients in the United...

2014-05-16 08:25:56

CARLSBAD, Calif., May 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Day Presentation When: Thursday, May 22 at 12:00 p.m. ET /9:00 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. If you are unable to...

2014-05-15 08:31:23

CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our...

2014-05-14 08:29:48

Greater than 2 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., May 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from a Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol efficacy population treated with ISIS-GCGR(Rx) achieved statistically significant reductions in measures of glucose...

2014-05-13 16:29:02

CARLSBAD, Calif., May 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 8:00 a.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com....

2014-05-08 08:32:07

CARLSBAD, Calif., May 8, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 11:20 a.m. PT in Las Vegas, NV. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's...

2014-05-07 12:29:28

Amplimmune, Inc. and Medimmune are honored as the best deals in Mergers and Acquisitions and Isis Pharmaceuticals and Biogen Idec for Biopharmaceutical Licensing PHILADELPHIA, May 7, 2014 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, honored Amplimmune, Inc. and Medimmune for their work in pharmaceutical Mergers and Acquisitions (M&A), and Isis...

2014-05-06 08:35:15

-Conference Call Webcast Tuesday, May 6, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., May 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013. Isis' first quarter 2014 pro forma NOL was higher than the same period last year primarily due to variations in the timing of milestone...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related